CD9 Antibody (YA7185)

(Synonyms: CD9; MIC3; TSPAN29; GIG2; CD9 antigen; 5H9 antigen; Cell growth-inhibiting gene 2 protein; Leukocyte antigen MIC3; Motility-related protein; MRP-1; Tetraspanin-29; Tspan-29; p24; CD antigen CD9)
3 Cited Publications
Customer Review

Based on 3 publication(s) in Google Scholar

CD9 Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD9.

For research use only. We do not sell to patients.
  • Host:

    Rabbit

  • Isotype:

    IgG

  • Application:

    WB, IHC-P, ICC/IF, IP, FC

  • Reactivity :

    Human, Mouse, Rat

  • Formulation:

    Supplied in Rabbit IgG in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA.

  • Conjugation:
    Non-conjugated

Applications

Application
WB Info
WB: Western Blot
IHC-P Info
IHC-P: Immunohistochemistry-Paraffin
ICC/IF Info
ICC/IF: Immunocytochemistry/
Immunofluorescence
IP Info
IP: Immunoprecipitation
FC Info
FC: Flow Cytometry
Dilution Ratio 1:500-1:1000 1:50-1:100 1:50-1:200 1:20 1:50-1:100

Product Details

Description

CD9 Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD9.

  • Host Rabbit
  • Clonality Monoclonal,Recombinant
  • Species Reactivity
    Human, Mouse, Rat
  • Observed Molecular Weight
    Observed band size: 25 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 25 kDa
Immunogen

Synthetic peptide corresponding to Human CD9.The exact sequence is proprietary to MCE.

Purification

affinity purified

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

RRID

AB_3718724

Product Properties

  • Appearance

    Solution

  • Formulation

    Supplied in Rabbit IgG in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA.

  • Concentration

    Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration

  • Shipping

    Shipping with blue ice.

Verification Images

  • Experimental Validation Results for CD9 Antibody (YA7185)
    Western blot analysis of extracts from Hela(lane2(20μg), MCF-7(lane3(20μg), HepG2(lane4(20μg) and Jurkat(lane5(20μg) using CD9 Antibody (YA7185)(HY-P80610A). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight. The primary antibody (1/800) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST for 2 hour at room temperature. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001, 1/10,000) was used for 1 hour at room temperature.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Immunohistochemical analysis of paraffin-embedded human Breast Cancer tissue using CD9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Immunohistochemical analysis of paraffin-embedded human Esophageal Carcinoma tissue using CD9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Immunohistochemical analysis of paraffin-embedded human ovarian carcinoma tissue using CD9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Immunohistochemical analysis of paraffin-embedded human Cervical cancer tissue using CD9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Immunohistochemical analysis of paraffin-embedded human Cervical cancer tissue using CD9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Immunohistochemical analysis of paraffin-embedded human Tonsil tissue using CD9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Breast Cancer tissue using CD9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃ and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Breast Cancer tissue using CD9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃ and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Breast Cancer tissue using CD9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃ and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Tonsil tissue using CD9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃ and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Tonsil tissue using CD9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃ and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Tonsil tissue using CD9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P80610A, 1:50 dilution) at room temperature for Leave overnight at 4 ℃ and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Flow cytometric analysis of 1X106 HeLa cells labeling CD9 Antibody (HY-P80610A, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/50 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Rabbit IgG H&L (HY-P8002) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Rabbit IgG Isotype Control (HY-P80879, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Immunocytochemistry analysis of HCT116 cells labeling CD9 with CD9 Antibody (HY-P80610A) at 1/100 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature, then blocked with quick block buffer for 10 minutes at room temperature. Cells were then incubated with CD9 Antibody (HY-P80610A) at 1/100 dilution in quick block buffer overnight at 4 ℃. AF488-conjugated Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).
  • Experimental Validation Results for CD9 Antibody (YA7185)
    Immunocytochemistry analysis of MCF-7 cells labeling CD9 with CD9 Antibody (HY-P80610A) at 1/100 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature, then blocked with quick block buffer for 10 minutes at room temperature. Cells were then incubated with CD9 Antibody (HY-P80610A) at 1/100 dilution in quick block buffer overnight at 4 ℃. AF488-conjugated Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).

Background

  • Function

    CD9 methylates (mono- and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in several proteins involved in DNA packaging, transcription regulation, pre-mRNA splicing, and mRNA stability. Recruited to promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 families, methylates histone H3 at 'Arg-17' (H3R17me), forming mainly asymmetric dimethylarginine (H3R17me2a), leading to activation of transcription via chromatin remodeling. During nuclear hormone receptor activation and TCF7L2/TCF4 activation, acts synergically with EP300/P300 and either one of the p160 histone acetyltransferases NCOA1/SRC1, NCOA2/GRIP1 and NCOA3/ACTR or CTNNB1/beta-catenin to activate transcription. During myogenic transcriptional activation, acts together with NCOA3/ACTR as a coactivator for MEF2C. During monocyte inflammatory stimulation, acts together with EP300/P300 as a coactivator for NF-kappa-B. Acts as a coactivator for PPARG, promotes adipocyte differentiation and the accumulation of brown fat tissue. Plays a role in the regulation of pre-mRNA alternative splicing by methylation of splicing factors. Also seems to be involved in p53/TP53 transcriptional activation. Methylates EP300/P300, both at 'Arg-2142', which may loosen its interaction with NCOA2/GRIP1, and at 'Arg-580' and 'Arg-604' in the KIX domain, which impairs its interaction with CREB and inhibits CREB-dependent transcriptional activation. Also methylates arginine residues in RNA-binding proteins PABPC1, ELAVL1 and ELAV4, which may affect their mRNA-stabilizing properties and the half-life of their target mRNAs. Acts as a transcriptional coactivator of ACACA/acetyl-CoA carboxylase by enriching H3R17 methylation at its promoter, thereby positively regulating fatty acid synthesis. Independently of its methyltransferase activity, involved in replication fork progression: promotes PARP1 recruitment to replication forks, leading to poly-ADP-ribosylation of chromatin at replication forks and reduced fork speed[1][2][3][4][5].

  • Subcellular Localization

    Cell membrane; Multi-pass membrane protein; Membrane ; Multi-pass membrane protein; Secreted, extracellular exosome

  • Expression


    Tissue_specificity:Protein levels were detected in platelets. It is expressed by various hematopoietic cells and epithelial cells.

  • Isoforms & Post-Translational Modification

    CD9 has an amino acid length of 228, molecular weight is 25416 Da.
    Palmitoylated at a low, basal level in unstimulated platelets. The level of palmitoylation increases when platelets are activated by thrombin (in vitro). The protein exists in three forms with molecular masses between 22 and 27 kDa, and is known to carry covalently linked fatty acids. Palmitoylation by ZDHHC2 regulates CD9 expression, association with other tetraspanin family proteins and function in cell adhesion.

  • Subunit

    Forms both disulfide-linked homodimers and higher homooligomers as well as heterooligomers with other members of the tetraspanin family. Interacts (via the second extracellular domain) with integrin ITGAV:ITGB3. Part of integrin-tetraspanin complexes composed of CD81, beta-1 and beta-2 integrins in the membrane of monocyte/macrophages. Interacts with CD63; identified in a complex with CD63 and ITGB3. Associates with CR2/CD21 and with PTGFRN/CD9P1. Interacts directly with IGSF8. Interacts with PDPN; this interaction is homophilic and attenuates platelet aggregation and pulmonary metastasis induced by PDPN. Interacts (on T cell side) with CD81 at immunological synapses between antigen-presenting cells and T cells.

  • SwissProt ID

    P21926

  • Gene ID
    928 [NCBI]
  • Synonyms

    CD9; MIC3; TSPAN29; GIG2; CD9 antigen; 5H9 antigen; Cell growth-inhibiting gene 2 protein; Leukocyte antigen MIC3; Motility-related protein; MRP-1; Tetraspanin-29; Tspan-29; p24; CD antigen CD9

References

CD9 Antibody (YA7185) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00